Figure 2

Longitudinal changes in the amount of MNC-NAIP, ALSFRS-R, and %FVC in 6 ALS patients. (A–F) The NAIP level at baseline, 4 months, 8 months, and 12 months from 6 ALS patients measured using dot blotting was quantitated per μg of whole protein extract from MNC (white bar). The ALSFRS-R and %FVC at baseline, 4 months, 8 months, and 12 months from 6 ALS patients are shown as black squares and gray triangles, respectively. Data are expressed as mean ± SD (n = 4 technical replicates). The information of each ALS patient is follows: (A) A 58-year-old man with upper limb type ALS and a disease duration of 16 months (A7); (B) A 71-year-old woman with bulbar type ALS and a disease duration of 18 months (A8); (C) A 58-year-old man with upper limb type ALS and a disease duration of 77 months (A9); (D) A 30-year-old man with lower limb type ALS and a disease duration of 16 months (A10); (E) A 65-year-old man with upper limb type ALS and a disease duration of 23 months (A11); (F) A 44-year-old woman with upper limb type ALS and a disease duration of 38 months (A12).